Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesChetan Bettegowda, Jon Weingart, Mark Sausen et al.|Science Translational Medicine|2014Cited by 5.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Patrizia Racca et al.|The Lancet Oncology|2016Cited by 1k
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancersAparna R. Parikh, Ryan B. Corcoran, Ignaty Leshchiner et al.|Nature Medicine|2019Cited by 521
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal CancerAparna R. Parikh, Ryan B. Corcoran, Emily E. Van Seventer et al.|Clinical Cancer Research|2021Cited by 358
Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal CancersAparna R. Parikh, Ryan B. Corcoran, Amikasra Mojtahed et al.|Clinical Cancer Research|2020Cited by 143